Показано 0 из 0
Дата |
---|
02.07.2024 |
01.07.2024 |
28.06.2024 |
27.06.2024 |
26.06.2024 |
25.06.2024 |
24.06.2024 |
21.06.2024 |
20.06.2024 |
18.06.2024 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
---|---|---|---|---|---|---|---|
227.09
|
234.00
|
229.06
|
227.69
|
231.14
|
229.24
|
|
|
151 715 842.38
|
16 464.00
|
228.92
|
233.00
|
233.76
|
229.12
|
237.705
|
229.27
|
|
|
244 154 429.21
|
18 308.00
|
228.75
|
240.00
|
232.27
|
230.51
|
234.84
|
233.71
|
|
|
561 494 364.05
|
30 451.00
|
229.30
|
231.25
|
232.28
|
229.07
|
232.98
|
230.94
|
|
|
339 599 900.17
|
25 550.00
|
230.00
|
231.63
|
234.055
|
230.69
|
234.61
|
231.62
|
|
|
392 766 708.53
|
26 628.00
|
232.20
|
236.15
|
235.28
|
233.18
|
235.51
|
233.87
|
|
|
240 815 095.16
|
17 951.00
|
233.59
|
238.00
|
238.73
|
235.33
|
239.56
|
235.91
|
|
|
211 765 077.62
|
18 807.00
|
229.09
|
239.56
|
239.58
|
237.27
|
239.58
|
238.29
|
|
|
480 272 331.25
|
20 352.00
|
235.56
|
240.00
|
233.15
|
232.08
|
239.26
|
238.40
|
|
|
393 162 922.25
|
27 463.00
|
229.28
|
240.00
|
232.41
|
231.94
|
234.7597
|
233.73
|
|
|
241 927 390.48
|
18 658.00
|
Период |
---|
2024, регулярные |
2024, регулярные |
2023, регулярные |
2023, регулярные |
2023, регулярные |
2022, регулярные |
2022, регулярные |
2022, регулярные |
2022, регулярные |
2022, регулярные |
Экс-дивидендная дата
|
Закрытие реестра |
Сумма выплаты |
---|---|---|
07.06.2024
|
10.06.2024 |
0.95 USD |
06.03.2024
|
08.03.2024 |
0.95 USD |
06.12.2023
|
08.12.2023 |
0.95 USD |
06.09.2023
|
08.09.2023 |
0.91 USD |
08.03.2023
|
10.03.2023 |
0.91 USD |
07.12.2022
|
09.12.2022 |
0.91 USD |
07.09.2022
|
09.09.2022 |
0.87 USD |
07.06.2022
|
09.06.2022 |
0.87 USD |
08.03.2022
|
10.03.2022 |
0.87 USD |
08.12.2021
|
10.12.2021 |
0.87 USD |
Becton, Dickinson and Company is a global medical technology company engaged principally in the development, manufacture, and sale of medical devices, instrument systems, and reagents used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public.